Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer
Academic Article
Publication Date:
2021
abstract:
In the PURE-01 study (NCT02736266), we aimed to evaluate the ability to predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers.
Iris type:
1.1 Articolo in rivista
Keywords:
Pembrolizumab; biomarkers; muscle-invasive bladder cancer; neoadjuvant immunotherapy; risk calculator
List of contributors:
Bandini, Marco; Ross, Jeffrey S; Raggi, Daniele; Gallina, Andrea; Colecchia, Maurizio; Lucianò, Roberta; Giannatempo, Patrizia; Farè, Elena; Pederzoli, Filippo; Bianchi, Marco; Colombo, Renzo; Gandaglia, Giorgio; Fossati, Nicola; Marandino, Laura; Capitanio, Umberto; Deho', Federico; Ali, Siraj M; Madison, Russell; Chung, Jon H; Salonia, Andrea; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea
Published in: